An open-label, single-arm Phase II study of intravenous weekly (Days 1 and 8) topotecan in combination with carboplatin (Day 1) every 21 days as second-line therapy in patients with platinum-sensitive relapsed ovarian cancer

Gynecologic Oncology

Volumn 120, Issue 1, 2011, Pages 38-42

  Rose, Peter G ^a   Monk, Bradley J ^b   Provencher, Diane ^c   Hartney, Jean ^d   Legenne, Philippe ^e   Lane, Stephen ^d  

^a METROHEALTH MEDICAL CENTER   (United States)

^b CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d GLAXOSMITHKLINE   (United States)

^e GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Carboplatin; Ovarian cancer; Platinum sensitive; Relapsed disease; Topotecan

Indexed keywords

CARBOPLATIN; TOPOTECAN;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OPEN STUDY; OVARY CARCINOMA; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RISK BENEFIT ANALYSIS; THROMBOCYTOPENIA; UTERINE TUBE TUMOR; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; TOPOTECAN;

EID: 78649907376     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.10.011     Document Type: Article

References (28)

1. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology™. Ovarian cancer including fallopian tube cancer and primary peritoneal cancer. V.2.2010. Available at: http://www.nccn.org/ professionals/physician-gls/PDF/ovarian.pdf. Accessed June 7, 2010.
2. R.F. Ozols, B.N. Bundy, and B.E. Greer Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study J Clin Oncol 21 2003 3194 3200
3. A. du Bois, H.J. Lück, and W. Meier A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer J Natl Cancer Inst 95 2003 1320 1329
4. C.L. Kosary Cancer of the ovary L.A.G. Ries, J.L. Young, G.E. Keel, SEER survival monograph: cancer survival among adults: U.S. SEER program, 1988-2001, patient and tumor characteristics. National Cancer Institute, SEER Program, NIH Pub. No. 07-6215, Bethesda, MD 2007 Available at: http://seer.cancer.gov/ publications/survival/. Accessed July 6, 2010
5. S.A. Cannistra Is there a "best" choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer? J Clin Oncol 20 2002 1158 1160
6. J.T. Thigpen, J.A. Blessing, and H. Ball Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study J Clin Oncol 12 1994 1748 1753
7. N. Colombo, and M. Gore Treatment of recurrent ovarian cancer relapsing 6-12 months post platinum-based chemotherapy Crit Rev Oncol Hematol 64 2007 129 138
8. J.A. Ledermann Randomised trial of paclitaxel in combination with platinum chemotherapy versus platinum-based chemotherapy in the treatment of relapsed ovarian cancer (ICON4/OVAR 2.2) Proc Am Soc Clin Oncol 22 2003 Abstract 1794
9. M.K. Parmar, J.A. Ledermann, and N. Colombo Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial Lancet 361 2003 2099 2106
10. A.J. González-Martin, E. Calvo, and I. Bover Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study Ann Oncol 16 2005 749 755
11. J. Pfisterer, M. Plante, and I. Vergote Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG J Clin Oncol 24 29 2006 4699 4707
12. E. Pujade-Lauraine, U. Wagner, and E. Aavall-Lundqvist Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse J Clin Oncol 28 20 2010 3323 3329
13. M.A. Bookman, H. Malmström, and G. Bolis Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel J Clin Oncol 16 1998 3345 3352
14. H.D. Homesley, D.J. Hall, and D.A. Martin A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients Gynecol Oncol 83 2001 394 399
15. R.T. Morris Weekly topotecan in the management of ovarian cancer Gynecol Oncol 90 2003 S34 S38
16. P.G. Rose, M. Smrekar, and P. Haba A phase I/II trial of weekly topotecan and carboplatin in potentially platinum-sensitive relapsed ovarian and peritoneal carcinoma Gynecol Oncol 99 2005 714 719 (Pubitemid 41686557)
17. P.E. Schwartz, P.G. Rose, and B.J. Monk An open-label, single arm, phase II study of IV weekly (days 1 and 8) topotecan in combination with carboplatin (day 1) every 21 days as second-line therapy in subjects with platinum-sensitive relapsed ovarian cancer: first stage results J Clin Oncol 26 2008 (May 20 suppl): Abstract 16518. Presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO); May 30-June 3, 2008; Chicago, Illinois
18. P. Schwartz, P. Rose, and B. Monk IV weekly (days 1 and 8) topotecan in combination with carboplatin (day 1) every 21 days as second-line therapy in subjects with relapsed ovarian cancer (OC): dose selection for a phase II study Int J Gynecol Cancer 19 suppl 2 2009 Presented at the 15th International Meeting of the International Society of Gynaecological Oncology (ESGO); October 28-November 1, 2007; Berlin, Germany
19. World Health Organization WHO handbook for reporting results of cancer treatment 1979 World Health Organization Geneva (Switzerland) Offset Publication No. 48
20. J. Pfisterer, M. Plante, and I. Vergote Gemcitabine/carboplatin (GC) vs. carboplatin (C) in platinum sensitive recurrent ovarian cancer (OVCA). Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG J Clin Oncol 22 2004 No. 14S; July 15 Supplement): Abstract 5005. Presented at the 40th Annual Meeting of the American Society of Clinical Oncology (ASCO); June 5-8, 2004; Denver, Louisiana
21. S.J. Green, and S. Dahlberg Planned versus attained design in phase II clinical trials Stat Med 11 7 1992 853 862
22. D. Bafaloukos, H. Linardou, and G. Aravantinos A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study BMC Med 8 2010 3
23. M.F. Kose, J. Sufliarsky, and S. Beslija A phase II study of gemcitabine plus carboplatin in platinum-sensitive, recurrent ovarian carcinoma Gynecol Oncol 96 2005 374 380
24. B.L. Rapoport, D.A. Vorobiof, and C. Slabber Phase II study of pegylated liposomal doxorubicin and carboplatin in patients with platinum-sensitive and partially platinum-sensitive metastatic ovarian cancer Int J Gynecol Cancer 19 2009 1137 1141
25. Food and Drug Administration's guidance for industry Clinical trial endpoints for the approval of cancer drugs and biologics May 2007 Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm071590.pdf. Accessed June 30, 2010
26. D. Koensgen, D. Stengel, and A. Belau Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study Cancer Chemother Pharmacol 62 2008 393 400 (Pubitemid 351871797)
27. K. Ushijima Treatment of recurrent ovarian cancer-at first relapse J Oncol 2010 2010 497429
28. N.S. Ali, and J.A. Ledermann Current practice and new developments in ovarian cancer chemotherapy Obstetrician Gynaecologist 9 2007 265 269